1. Novartis, Amgen and Mallinckrodt used aggressive price hikes to meet sales goals, congressional probe finds — Alnylam posts positive results of groundbreaking phase 3 PH1 trial — FDA expands probe into safety of AstraZeneca's COVID vaccine — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

The blind leading the blind

Discussion in 'Blue Belt Technologies' started by Anonymous, May 7, 2013 at 10:32 AM.

  1. Anonymous

    Anonymous Guest

    Blue Belt has sold exactly two systems in the US since launching in December and another "freehand" upstart is set to stir things up. Apparently, BBT's supposedly "vast" patent moat is crumbling further. Are E.T.'s handlers at H. Capital seeing dreams of a slick buyout vaporizing? Butt ugly Frankenstein products by both. Dear gawd I hope that's a prototype and not the finished product.
    http://www.omaha.com/article/20130415/LIVEWELL01/704159967